Literature DB >> 17496929

Eighth international mesothelioma interest group.

M Carbone1, S M Albelda, V C Broaddus, R M Flores, G Hillerdal, M-C Jaurand, K Kjaerheim, H I Pass, B Robinson, A Tsao.   

Abstract

The eighth International Mesothelioma Interest Group (IMIG) meeting was held in Chicago, IL, United States, in 19-22 October 2006 to discuss mesothelioma - the cancer often linked to asbestos exposure. It is a very aggressive malignancy with a median survival of less than 1 year from diagnosis. Millions of people have been exposed worldwide to asbestos, especially during the second half of the twentieth century when asbestos use increased significantly. The tons of asbestos utilized in the past remain a health hazard for current and future generations because asbestos is difficult to be disposed off. This makes asbestos and mesothelioma research a public health issue in addition to a medical problem. Moreover, the very high costs of asbestos litigation have a significant impact on the whole economy. In the United States, up until 2001, defendant companies had paid 54 billion dollars in claims and estimated future liabilities ranged from 145 to 210 billion. Therefore, asbestos research is of great interest to a large audience that includes patients, millions of asbestos-exposed individuals, scientists, physicians, public health officials, politicians, unions of asbestos workers, lawyers and the public at large. During the past few years, there has been significant progress in understanding the process of mineral fiber carcinogenesis and mesothelioma pathogenesis. With improved understanding of the pathogenesis of mesothelioma, new diagnostic, preventive and therapeutic options are being developed. A total of 247 papers were presented at the IMIG: the abstracts of these presentations were published in Lung Cancer, Supplement 1, October 2006. Here, experts in different disciplines critically review some of the most exciting presentations of the IMIG meeting. The result is a comprehensive review of the research field of asbestos carcinogenesis and mesothelioma, and of the progress that has been made in recent years in both basic and clinical sciences.

Entities:  

Mesh:

Year:  2007        PMID: 17496929     DOI: 10.1038/sj.onc.1210515

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

Review 1.  Malignant mesothelioma: facts, myths, and hypotheses.

Authors:  Michele Carbone; Bevan H Ly; Ronald F Dodson; Ian Pagano; Paul T Morris; Umran A Dogan; Adi F Gazdar; Harvey I Pass; Haining Yang
Journal:  J Cell Physiol       Date:  2012-01       Impact factor: 6.384

2.  Tissue Tropism of SV40 Transformation of Human Cells: Role of the Viral Regulatory Region and of Cellular Oncogenes.

Authors:  Lei Zhang; Fang Qi; Giovanni Gaudino; Oriana Strianese; Haining Yang; Paul Morris; Harvey I Pass; Vivek R Nerurkar; Maurizio Bocchetta; Michele Carbone
Journal:  Genes Cancer       Date:  2010-10

3.  Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.

Authors:  Najmunnisa Nasreen; Nazli Khodayari; Kamal A Mohammed
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

4.  BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients.

Authors:  Julija Hmeljak; Nina Erčulj; Vita Dolžan; Izidor Kern; Andrej Cör
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-23       Impact factor: 4.553

5.  Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells.

Authors:  Esther Z Chen; Blake A Jacobson; Manish R Patel; Aniekan M Okon; Shui Li; Kerry Xiong; Abhishek J Vaidya; Peter B Bitterman; Carston R Wagner; Robert A Kratzke
Journal:  Invest New Drugs       Date:  2014-04-09       Impact factor: 3.850

6.  Ranpirnase Interferes with NF-κB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth.

Authors:  Masaki Nasu; Michele Carbone; Giovanni Gaudino; Bevan H Ly; Pietro Bertino; David Shimizu; Paul Morris; Harvey I Pass; Haining Yang
Journal:  Genes Cancer       Date:  2011-05

7.  Is survivin expression prognostic or predictive in malignant pleural mesothelioma?

Authors:  Julija Hmeljak; Nina Erčulj; Vita Dolžan; Jože Pižem; Izidor Kern; Viljem Kovač; Maja Cemažar; Andrej Cör
Journal:  Virchows Arch       Date:  2013-01-29       Impact factor: 4.064

Review 8.  Malignant pleural mesothelioma: current and future perspectives.

Authors:  Konstantinos Porpodis; Paul Zarogoulidis; Efimia Boutsikou; Antonis Papaioannou; Nikolaos Machairiotis; Kosmas Tsakiridis; Nikolaos Katsikogiannis; Bojan Zaric; Branislav Perin; Haidong Huang; Ioanna Kougioumtzi; Dionysios Spyratos; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

9.  Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis.

Authors:  Arti Shukla; Marcus W Bosenberg; Maximilian B MacPherson; Kelly J Butnor; Nicholas H Heintz; Harvey I Pass; Michele Carbone; Joseph R Testa; Brooke T Mossman
Journal:  Am J Pathol       Date:  2009-10-08       Impact factor: 4.307

10.  A novel mechanism of late gene silencing drives SV40 transformation of human mesothelial cells.

Authors:  Michele Carbone; Antonio Pannuti; Lei Zhang; Joseph R Testa; Maurizio Bocchetta
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.